Ligand Pharmaceuticals | LGND - Ebit


Ligand Pharmaceuticals reported $158.89M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Agenus USD -13.31M 19.08M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Enviri Corporation USD -35.28M 61.58M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025